TOS.TO - TSO3 Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.4200
+0.0025 (+0.60%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.4175
Open0.4150
Bid0.4200 x 0
Ask0.4250 x 0
Day's Range0.4150 - 0.4200
52 Week Range0.2800 - 0.7200
Volume392,080
Avg. Volume177,067
Market Cap39.275M
Beta (3Y Monthly)5.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    TSO3 Reports Second Quarter 2019 Results

    QUEBEC CITY and MYRTLE BEACH, SC, Aug. 12, 2019 /PRNewswire/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, reports financial results for the second quarter ended June 30, 2019. The Company's net loss was $(4.2) million or $(0.045) per share in the second quarter of 2019, as compared to $(3.4) million or $(0.04) per share in the first quarter of 2019 and $(4.0) million or $(0.04) per share in the year-ago quarter.

  • PR Newswire

    TSO3 Inc. Enters into Agreement to be Acquired by Stryker Corporation

    QUÉBEC CITY and MYRTLE BEACH, SC, Aug. 12, 2019 /PRNewswire/ - TSO3 Inc. ("TSO3" or the "Company") (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which 9402-4874 Québec Inc. (the "Purchaser"), a subsidiary of Stryker Corporation ("Stryker"), will acquire all of the issued and outstanding common shares (the "Shares") of the Company for $0.43 in cash per Share (the "Purchase Price"), subject to adjustment in the event the transaction expenses are greater than currently anticipated. The Company does not currently expect any adjustment to be made to the Purchase Price and in the event such an adjustment would be required, that it would be minimal.

  • CNW Group

    TSO3 Announces Group Purchasing Agreement with Capstone Health Alliance

    TSO3 Announces Group Purchasing Agreement with Capstone Health Alliance

  • PR Newswire

    TSO3 Announces the Vote Results from its Annual Meeting of the Shareholders

    QUEBEC CITY and MYRTLE BEACH, SC , May 8, 2019 /PRNewswire/ - TSO3 Inc. (TSX: TOS), ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswire

    TSO3 Reports First Quarter 2019 Results

    QUEBEC CITY and MYRTLE BEACH, SC , May 6, 2019 /PRNewswire/ - TSO3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • CNW Group

    TSO3 Announces the Dates of its First Quarter 2019 Earnings Conference Call and Annual General Meeting of Shareholders

    QUEBEC CITY , QC and MYRTLE BEACH, SC , April 30, 2019 /CNW Telbec/ - TSO3 Inc. (TOS.TO), ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call to discuss its financial results for the first quarter ended March 31, 2019 and will hold its Annual General Meeting of Shareholders on Tuesday, May 7, 2019 .

  • CNW Group

    TSO3 Announces Changes to the Board of Directors

    MYRTLE BEACH, SC and QUEBEC CITY, April 2, 2019 /CNW Telbec/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has appointed Sara Elford to the Company's board of directors and further announced the resignation of Douglas Dieter . Ms. Elford enjoyed a long and successful career in Canadian capital markets.

  • PR Newswire

    TSO3 Reports Fourth Quarter and Full Year 2018 Results

    QUEBEC CITY and MYRTLE BEACH, SC , March 27, 2019 /PRNewswire/ - TSO 3 Inc. (TSX: TOS) ("TSO 3 " or the "Company"), an innovator in sterilization technology for medical devices in healthcare ...

  • PR Newswire

    TSO3 Announces Date of Fourth Quarter and Full Year 2018 Earnings Conference Call

    QUEBEC and MYRTLE BEACH, FL, March 21, 2019 /PRNewswire/ - TSO3 Inc. (TOS.TO) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Thursday, March 28, 2019, to discuss its financial results for the fourth quarter and full year ended December 31, 2018. Financial results will be issued in a press release prior to the call. TSO3 President and CEO R.M. (Ric) Rumble and CFO Glen Kayll, will host the conference call, followed by a question and answer period.

  • CNW Group

    TSO3 Expands Duodenoscope Sterilization Testing

    QUÉBEC CITY and MYRTLE BEACH, SC , March 14, 2019 /CNW Telbec/ - TSO3 Inc. ("TSO3" or the "Company") (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has initiated sterilization testing intended to support repeated sterile reprocessing in the TSO3 STERIZONE® VP4 Sterilizer of the Fujifilm ED-530XT duodenoscope supplied by FUJIFILM Medical Systems U.S.A. , Inc. "Since 2016, we have been actively pursuing US regulatory clearance of our patented STERIZONE® VP4 Sterilizers to address growing concerns with existing reprocessing protocols used by medical facilities and specifically in gastrointestinal departments.

  • TSO3 Achieves Commercial Milestone and Provides Operational Update
    PR Newswire

    TSO3 Achieves Commercial Milestone and Provides Operational Update

    MYRTLE BEACH, SC and QUEBEC CITY, Jan. 7, 2019 /PRNewswire/ - TSO3 Inc. ("TSO3" or the "Company") (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, today announced that during its fourth fiscal quarter ending December 31, 2018, the Company received an order for the 100th unit of its industry-leading STERIZONE® VP4 Sterilizer. In addition to announcing this milestone, the Company also provided an update on its 2018 operational and commercialization activities. During the fourth quarter of 2018, the Company received purchase orders from US and Canadian customers for 21 sterilizers, which represents the highest order rate in the Company's history.

  • ACCESSWIRE

    Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • ACCESSWIRE

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • CNW Group

    American Journal of Infection Control publishes TSO3 study on terminal sterilization of duodenoscopes

    QUÉBEC CITY, QC and MYRTLE BEACH, SC , Nov. 15,  2018 /CNW Telbec/ - TSO3 Inc. ("TSO3" or the "Company") (TOS.TO), an innovator in sterilization technology for medical devices in healthcare settings, announces today that the results of the Company's clinical in-use and simulated use testing of the terminal sterilization of duodenoscopes have been published in the American Journal of Infection Control.  The paper describes innovative testing methods developed and deployed by the Company in support of its STERIZONE® VP4 Sterilizer, which has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA), for terminal sterilization of multi-channeled, flexible endoscopes that fall within the specified indications for use, including duodenoscopes.